Navigation Links
BiondVax Begins Phase IIa Study for Universal Flu Vaccine
Date:10/11/2010

BiondVax Begins Phase IIa Study for Universal Flu Vaccine -- NESS ZIONA, Israel, Oct. 11 /PRNewswire-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Infection Control, Medical Pharmaceuticals, Pharmaceuticals, Clinical Trials & Medical Discoveries Click to view news release full screen  

BiondVax Begins Phase IIa Study for Universal Flu Vaccine

 

NESS ZIONA, Israel, Oct. 11 /PRNewswire-FirstCall/ -- BiondVax Pharmaceuticals Ltd. (TASE: BNDX), an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, today announced that it has begun to immunize subjects in a Phase IIa clinical trial of the Multimeric-001 Universal Flu Vaccine candidate. The study will evaluate the safety and immunogenicity of the Multimeric-001 vaccine.  The vaccine is comprised of a unique, proprietary combination of conserved epitopes from influenza virus proteins, designed to stimulate both humoral (antibody-mediated) and cell-mediated immunity against both Type A and Type B influenza strains, and is thereby intended to provide protection against all seasonal and pandemic flu strains.

The Phase IIa study is a randomized, double-blind, placebo-controlled, multi-center, safety and immunogenicity study in 200 healthy volunteers.  The study is being conducted at two clinical research centers in Israel, the Hadassah Clinical Research Center at Hadassah University Hospital in Jerusalem ("Hadassah") and the Tel Aviv Sourasky Medical Center ("Ichilov").  The principal investigators conducting the clinical trial are Prof. Yoseph Caraco, Director of the Clinical Research Center at Hadassah and Dr. Jacob Atsmon, Director of the Clinical Research Center at Ichilov.

Dr. Ron Babecoff, BiondVax's President and CEO, said, "The commencement of this Phase IIa study is a major milestone in the clinical development of the Multimeric-001 universal influenza vaccine.  After the excellent results we achieved in our two previous Phase I/II trials, in which the Multimeric-001 vaccine was shown to be safe and immunogenic in both younger and older adults, we are excited to be embarking on this new important phase in the development of the universal influenza vaccine."

In the study, a total of 200 subjects, both male and female, 18-49 years old, will be divided into six groups, enabling the assessment of the safety and immunogenicity of the Multimeric-001 firstly as a standalone vaccine, secondly as a primer for a subsequent partial dose of a commercially available trivalent inactivated vaccine (TIV), and lastly when the Multimeric-001 vaccine is co-administered together with a TIV.

Participants in the first group will receive two 500 microgram doses of an adjuvanted formulation of the Multimeric-001 vaccine (the formulation that performed best in the previous Phase I/II trials), 21 days apart.  These participants will then receive a subsequent partial (15%) dose of a TIV, 60 days after their second immunization.  Participants in this treatment group will be compared against two control groups: one group that will receive two administrations of placebo 21 days apart, also followed 60 days later by a partial (15%) dose of TIV, and another group that will only receive two administrations of adjuvanted placebo, 21 days apart.  

Participants in the fourth and fifth groups will receive a single 500 microgram dose of the adjuvanted formulation of the Multimeric-001 vaccine, co-administered with either a 15% or 50% dose of the TIV, respectively.  These groups will be compared against a control group that will receive a placebo formulation co-administered with the higher of the two TIV doses.

The primary objectives of the Phase IIa study are to assess safety and immunogenicity, as measured by the level of IgG antibodies to the Multimeric-001 vaccine.  The secondary objectives of the study are to measure additional antibody and cellular immune responses, in particular neutralization by complement, Hemagglutination inhibition (HI) responses (a measure of protection) against various strains of influenza, as well as proliferation of Interleukin-2 (IL-2) and Interferon-gamma cytokines.  The company expects to report study results by mid-2011.For further information, please contact:Danny Aronovic
Public Relations Consultant
shapira marketing

Tel: +972 9 899 5813
Mob: +972 50 799 1121
danny@gksmarketing.com About BiondVax Pharmaceuticals Ltd.BiondVax Pharmaceuticals ("the Company"), a publicly-traded company (TASE: BNDX) based in Ness Ziona, Israel, is developing a proprietary, innovative Universal Influenza ("flu") Vaccine, the Multimeric-001 vaccine, designed to provide multi-season and multi-strain protection against all human influenza virus strains, including both seasonal influenza strains as well as pandemic influenza strains, such as Swine flu and Avian flu.

BiondVax's proprietary technology utilizes a unique, proprietary combination of conserved epitopes from influenza virus proteins to activate the immune system for a cross-protecting and long-lasting effect.

BiondVax has successfully concluded two Phase I/II trials in which the Multimeric-001 Universal Flu Vaccine was shown to be safe and immunogenic.  The Company is now conducting a Phase IIa study, expected to be completed by mid-2011.

For further information on BiondVax, please visit www.biondvax.com
'/>"/>

SOURCE BiondVax Pharmaceuticals Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals Universal Flu Vaccine
2. LIG Assets, Inc. Begins Distribution and Marketing of Unique CPAP Mask Cleaner
3. China PharmaHub Corp. Begins Trading Under Stock Symbol CPHB Instead of WRLC
4. Hospira Begins Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
5. Sysmex America Begins Distribution of CellaVision® DM1200
6. Renhuang Begins Trading on NYSE Amex
7. Par Pharmaceutical Begins Shipment of Generic Zegerid®
8. Curemark Begins Autism Trials at Two More Sites
9. ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
10. The Wellcore System Begins Shipping Featuring the Most Advanced Automatic Fall Detection Available
11. ADVENTRX Reverse Split Effective; Trading on Adjusted Basis Begins Today
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 ... Tomorrow,s Leaders Scholarship is any indication, the future is ... online at www.diabetesscholars.org by the Diabetes Scholars ... in the way of academic and community service excellence. ... program since 2012, and continues to advocate for people ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize each ... Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into hand ... select a ProHand generator and drag it above media or text in the Final ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):